XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma
Clinical trial NCT02721459 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT02721459
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2016-09-07
- Primary completion
- 2019-10-31
- Enrollment
- 26
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.